Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.About:
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.read more
Citations
More filters
Journal ArticleDOI
Blood Pressure and Stroke An Overview of Published Reviews
TL;DR: The epidemiologically expected benefits of BP lowering for stroke risk reduction are broadly consistent across a range of different population subgroups and initiating and maintaining BP reduction for stroke prevention is a more important issue than choice of initial agent.
Journal ArticleDOI
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
George L. Bakris,George L. Bakris,George L. Bakris,Vivian Fonseca,Vivian Fonseca,Richard E. Katholi,Richard E. Katholi,Janet B. McGill,Franz H. Messerli,Franz H. Messerli,Franz H. Messerli,Robert A. Phillips,Philip Raskin,Jackson T. Wright,Rosemary Oakes,Mary Ann Lukas,Karen M. Anderson,David S.H. Bell,David S.H. Bell +18 more
TL;DR: Use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension.
Journal ArticleDOI
Telmisartan to prevent recurrent stroke and cardiovascular events.
Salim Yusuf,Salim Yusuf,Hans-Christoph Diener,Ralph L. Sacco,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +34 more
TL;DR: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.
Journal ArticleDOI
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.
Kaberi Dasgupta,Robert R. Quinn,Kelly B. Zarnke,Doreen M. Rabi,Pietro Ravani,Stella S. Daskalopoulou,Simon W. Rabkin,Luc Trudeau,Ross D. Feldman,Lyne Cloutier,Ally P.H. Prebtani,Robert J. Herman,Simon L. Bacon,Richard E. Gilbert,Marcel Ruzicka,Donald W. McKay,Tavis S. Campbell,Steven A. Grover,George Honos,Ernesto L. Schiffrin,Peter Bolli,Thomas W. Wilson,Patrice Lindsay,Michael D. Hill,Shelagh B. Coutts,Gord Gubitz,Mark Gelfer,Michel Vallée,G. V. Ramesh Prasad,Marcel Lebel,Donna McLean,J. Malcolm O. Arnold,Gordon W. Moe,Jonathan G. Howlett,Jean-Martin Boulanger,Pierre Larochelle,Lawrence A. Leiter,Charlotte Jones,Richard I. Ogilvie,Vincent Woo,Janusz Kaczorowski,Kevin D. Burns,Robert J. Petrella,Swapnil Hiremath,Alain Milot,James A. Stone,Denis Drouin,Kim L. Lavoie,Maxime Lamarre-Cliche,Guy Tremblay,Pavel Hamet,George Fodor,S. George Carruthers,George Pylypchuk,Ellen Burgess,Richard Lewanczuk,George K. Dresser,S. Brian Penner,Robert A. Hegele,Philip A. McFarlane,Milan Khara,Andrew L. Pipe,Paul Oh,Peter Selby,Mukul Sharma,Debra Reid,Sheldon W. Tobe,Raj Padwal,Luc Poirier +68 more
TL;DR: The Canadian Hypertension Education Program reviews the hypertension literature annually and provides detailed recommendations regarding hypertension diagnosis, assessment, prevention, and treatment, and 4 new recommendations were added and 2 existing recommendations were modified this year.
Journal ArticleDOI
Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary.
Alan J. Garber,Martin J. Abrahamson,Joshua I. Barzilay,Lawrence Blonde,Zachary T. Bloomgarden,Michael A. Bush,Samuel Dagogo-Jack,Ralph A. DeFronzo,Daniel Einhorn,Vivian Fonseca,Jeffrey R. Garber,W. Timothy Garvey,George Grunberger,Yehuda Handelsman,Robert R. Henry,Irl B. Hirsch,Paul S. Jellinger,Janet B. McGill,Jeffrey I. Mechanick,Paul D. Rosenblit,Guillermo E. Umpierrez +20 more
TL;DR: This chapter discusses the development and use of eicosapentaenoic acid as a treatment for diabetic ketoacidosis and its applications in conventional and regenerative medicine.
References
More filters
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
An updated coronary risk profile. A statement for health professionals.
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more